Key result
Unfractionated heparin dominates ECMO anticoagulation while anti-Xa and viscoelastic assays emerge to personalize therapy.
Why the study?
ECMO requires careful management of anticoagulation to prevent thromboembolic complications while balancing the risks of thrombosis and bleeding.
Population
Patients with severe respiratory or cardiac failure receiving ECMO
Design
Narrative review
Authors
Loading...
Supports individualized ECMO anticoagulation; leaves open optimal monitoring strategies pending prospective trials.
Anticoagulation management in ECMO requires individualized approaches balancing thrombosis and bleeding risks, with unfractionated heparin remaining the standard but alternative monitoring and agents emerging.
Vajter et al. (2025) conducted a review in Severe respiratory or cardiac failure requiring ECMO. Anticoagulation management was evaluated. Unfractionated heparin remains the most commonly used anticoagulant during ECMO, with alternative tools like anti-Xa and viscoelastic assays emerging to improve personalized therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: